# Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder

> **NCT01254305** · PHASE2 · COMPLETED · sponsor: **Forest Laboratories** · enrollment: 262 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Levomilnacipran ER
- **DRUG:** Paroxetine, Sertraline, Citalopram or Fluoxetine.
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01254305
- **Lead sponsor:** Forest Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 262 (ACTUAL)
- **Last updated:** 2014-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01254305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01254305, "Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01254305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*